Genes encoding the p35 and p40 subunits of human interleukin -12 ( IL -12 ) and the bacterial aminoglycoside phosphotransferase were cloned into a mammalian expression plasmid. The resultant plasmid, pCMVIL -12neo, was used to transfect human lung tumor cell lines in vitro. Stably transfected subclones were generated and found to secrete human IL -12 for at least 10 days following a lethal dose of -radiation. The ability of the IL -12 ± producing tumor cells to promote an antitumor response in vivo was evaluated in SCID mice co -engrafted subcutaneously with human peripheral blood lymphocytes ( PBLs ) and viable human lung tumor cells ( SCID -Winn assay ). Using this model system, it was established that IL -12 released locally into tumors by irradiated IL -12 ± transfected cells activated the human PBL and promoted their ability to suppress tumor development in a dose -dependent fashion. PBL subset depletion studies revealed that the antitumor effect promoted by the IL -12 ± modified cells was dependent on the presence of human CD8 + T cells and, to a lesser extent, human CD56 + natural killer cells within the xenograft. We conclude that ( a ) irradiated human lung tumor cells genetically modified with pCMVIL -12neo secrete bioactive human IL -12 at concentrations sufficient to promote a human lymphocyte -mediated antitumor response in the microenvironment of the xenograft, and ( b ) that the SCID -Winn assay provides a useful model for the preclinical evaluation of cytokine -based human immunotherapy protocols.
T he ability of cytokine gene ± modified tumor cell vaccines to induce effective systemic antitumor immunity in transplantable murine tumor models is well established ( reviewed in Refs. 1, 2 ). Duplication of similar success in human patients, however, has been more elusive in phases I and II clinical trials, where efficacy has been limited to sporadic tumor remissions and occasional evidence of antitumor immunity. 3 ± 6 Although it is unrealistic, and perhaps unfair, to compare the results obtained in highly manipulable preclinical murine tumor models to those obtained in human patients with advanced disease and high tumor burden, the need for a better understanding and further improvement of cytokine -based tumor vaccination protocols is evident. 7, 8 One aspect of the bench -to -bedside process, which has not been sufficiently explored, involves the in vivo evaluation of the human cytokine expression vectors and the determination of optimal doses, schedules, and inoculation routes prior to clinical testing. In contrast to the murine vectors, which are tested and manipulated extensively in mouse models for optimal results, the preclinical testing of human vectors is largely limited to in vitro assays for obvious ethical reasons. Thus, the development of in vivo human tumor models that allow more rigorous preclinical evaluation of human vectors could result in a better understanding of their function in the human environment and possibly lead to the design of clinically more efficacious protocols.
We have developed a human peripheral blood leukocyte ( PBL ) /human tumor SCID mouse xenograft model for the purpose of monitoring patients' antitumor immunity in vivo.
Using this model, we demonstrated that the PBLs obtained from healthy donors or cancer patients possess antitumor activity, and that co-engraftment of PBL and tumor results in a PBL dose -dependent suppression of tumor growth in SCID mice. In addition, the antitumor activity of the PBL could be augmented by the systemic administration of soluble cytokines in the SCID -Winn model. 9 Here, we utilize the SCID -Winn assay to evaluate the antitumor efficacy of a human interleukin -12 (IL -12) expression plasmid ( pCMVIL -12neo ) following its transfection into human lung tumor cells. The data establish that pCMVIL12neo± transfected human tumor cells promote a CD8 + Tcell ± and natural killer ( NK ) cell ±dependent antitumor activity of human PBL, and that the SCID -Winn assay provides an effective tool for in vivo evaluation of human cytokine expression vectors.
MATERIALS AND METHODS

Mice
CB -17 scid /scid were obtained from our breeding colony. All mice were maintained in microisolation cages (Lab Products, Federalsburg, MA ) under pathogen -free conditions. Animals of both sexes were used in the studies at 8 ± 12 weeks of age.
Human tumor cells
Human squamous cell lung carcinoma cell lines RPCI -2E9 and RPCI -9597 were originally established in our laboratory from patient specimens surgically resected at Roswell Park Cancer Institute. Both cell lines were characterized as MHC class I ±positive and MHC class II ± negative by FACS ( data not shown ). The cell lines were maintained in DMEM /F -12 ( Life Technologies, Grand Island, NY ), supplemented with 10% heat -inactivated fetal calf serum at 378C in 5% CO 2 . Cultured cells were allowed to grow to 80% confluence and were harvested with 0.25% trypsin +1 mM EDTA in Dulbecco's modified Eagle's medium (DMEM ).
Construction of the pCMVIL -12neo plasmid
The cDNA for the p35 and p40 subunits of human IL -12 were obtained from Dr. Stanley Wolf (Genetics Institute, Andover, MA ). The cDNA for p40 was removed from the plasmid pED40 with SalI+SmaI digest, end-filled, and cloned into the NotI site of the mammalian expression vector pCMV (Clontech, Palo Alto, CA ) by blunt -end ligation following removal of the LacZ gene (pCMV40 ). The p35 cDNA was removed from the plasmid pED35 by digestion with PstI and SspI, end-filled, and cloned into the MscI site of the expression vector pCITE4a (Novagen, Madison, WI ) by blunt -end ligation downstream of the viral internal ribosomal entry site ( IRES ). The cassette containing the IRES -p35 sequence was then removed from this plasmid by digesting with PvuII and NdeI and was cloned into pCMV40 digested with EcoRV + AflII downstream of the p40 cDNA ( plasmid pCMVIL-12, $6.7 kb ). The Escherichia coli aminoglycoside phosphotransferase gene, which confers neomycin resistance, was obtained from the plasmid pMAMneo (Clontech ) by digestion with BamHI, end-filled, and cloned into the SalI site of pCMVIL -12 by blunt -end ligation (plasmid pCMVIL -12neo, $9.4 kb ).
Transfection and selection of clones
Tumor cells were transfected in vitro with pCMVIL -12neo using the LipofectAMINE PLUS Reagent kit as recommended by the supplier (Life Technologies ). Briefly, 5 g plasmid DNA, precomplexed with 20 L PLUS Reagent, was mixed with 40 nmol lipid (lipid:DNA ratio =8 nmol:1 g) in serum -free medium and incubated for 15 minutes at room temperature. Tumor cells (60 ± 80% confluent) in 10-cm culture dishes were washed twice with serum -free medium and lipid ±plasmid DNA mixture was added to cells in total of 5 mL serum -free medium. Following incubation of cells at 378C, 5% CO 2 for 4 hours, transfection medium was replaced with 10 mL complete medium ( DMEM /F -12 +10% FCS ) and cells were cultured overnight at 378C.
Stably transfected clones were selected in medium supplemented with G418 ( 1 mg / mL ) by limiting dilution in 96-well plates. Clones were screened by testing the supernatants from the wells for human IL-12 by enzyme -linked immunosorbent assay ( ELISA ) ( see below ).
In vitro cytokine release
Stably transfected clones were harvested from culture, washed twice in DMEM, and counted by trypan blue exclusion. Irradiation of cells was carried out using a cesium source to deliver 3500 rad (947 rad /min ) to cells suspended in 10 mL DMEM in 15 -mL conical tubes. Cells were plated at a concentration of 1Â10 6 /well in six -well plates in 2 mL DMEM /F -12 complete medium ( without G418 ) and incubated at 378C. The medium was changed daily for 10 days; aliquots were microcentrifuged briefly to pellet dead cells/ debris, and supernatant was stored at À 808C. The quantity of IL -12 in the supernatant was determined by ELISA as described below.
Tumor and PBL engraftment
Human PBLs were obtained from healthy donors as described before.
9 RPCI -2E9 tumor cells ( 1Â10 6 ) and human PBL (2Â10 6 ) were mixed with varying doses of irradiated RPCI -9597 ± IL-12 cells ( see figure legends for details ) and injected subcutaneously (s.c. ) into the ventral ± caudal midline region of SCID mice. Tumor volume was determined weekly by the formula (A + B 2 )/2 where A and B are the long and short dimensions of the tumor in millimeters, respectively. PBL subset depletion was carried out as described previously. 9 All mice were depleted of murine NK cells 1 day prior to the inoculation of tumor + PBL by a single intraperitoneal (i.p. ) injection of the monoclonal antibody, TM -1 ( a generous gift from Dr. T. Tanaka, Tokyo Metropolitan Institute of Medical Science, Japan ), which is specific for the murine IL -2 receptorchain. 10 
In vivo neutralization of IL -12
The monoclonal antibody BH6, which blocks the activity of human IL -12, 11 was added directly to suspensions containing tumor cells, irradiated RPCI -9597± IL -12 cells, and PBL used for inoculation of mice. Each mouse received 50 g of antibody s.c. with the cell inoculum on day 0. Mice were given additional antibody injections on days 2 and 4 postinoculation (25 g /200 L, i.p. ). Control mice received the same dose of isotype control monoclonal antibody 2C3 ( mouse IgG, 1, K, antihapten phthalate ). Mice were bled retro-orbitally for serum collection on days 1, 3, 5, and 7 postinoculation of cells.
Cytokine ELISAs
Human IL -12 and IFN -were quantified using sandwich ELISAs, which detect the IL -12 p70 heterodimer and the IFN -homodimer. 9, 11 Microtiter plates were coated with the anticytokine antibodies (DA8 against IL -12, developed in our laboratory and M700A against IFN -; Endogen, Cambridge, MA ). Tissue culture medium or mouse sera, and cytokine standards (IL -12 from Genetics Institute, Cam-bridge, MA; IFN -from Endogen ) were added to the plates followed with biotinylated second anticytokine antibody ( BH6 for IL -12 from our laboratory and M701B for IFNfrom Endogen ). The bound antibody was detected with streptavidin ± horseradish peroxidase (1 g /mL; Sigma, St. Louis, MO ) and TMB (3,3,5,5-tetramethyl benzidene; Sigma).
RESULTS
Development of a human lung tumor cell line secreting human IL -12
A plasmid vector was constructed for constitutive expression of human IL -12. The cDNA for the p35 and p40 subunit chains of IL-12 were cloned into a mammalian expression plasmid downstream of the cytomegalovirus (CMV ) promoter with a viral internal ribosomal entry sequence inserted between the cDNA to allow co-translation of both chains from a single transcript. The E. coli neomycin resistance gene under the control of a separate promoter was also cloned into the same plasmid to select for stably transfected cell lines creating the plasmid pCMVIL -12neo ( Fig 1 ) . The lung tumor cell line RPCI -9597 was transfected with pCMVIL -12neo by liposome-mediated gene transfer, and clones stably expressing human IL -12 were derived following selection in media containing G418. The clone secreting the highest level of IL-12 ( $3.5 ng IL -12 /1Â10 6 cells/24 hours ) was identified and expanded (RPCI -9597 ± IL -12 ).
Because gene -modified tumor cells are lethally irradiated prior to administration into patients in the clinic, the effect of a lethal cell dose of -irradiation on the IL -12 secretion profile of RPCI -9597 ±IL -12 cells was monitored daily over a 10 -day period by assaying supernatants of cultured cells for the presence of hIL -12 by ELISA. As shown in Figure 2 , the pattern of IL -12 secretion from nonirradiated cells and lethally irradiated cells is similar for the first 5 days in culture. Subsequently, the amount of IL-12 produced by the irradiated cells declines ( due to cell death; data not shown ), whereas IL -12 secretion by nonirradiated cells increases. Both nonirradiated and irradiated cells continue to secrete detectable quantities of IL -12 for at least 10 days in culture.
IL -12 produced by irradiated RPCI -9597 ± IL -12 cells activates human PBL to produce IFN -and augments their antitumor activity in the SCID -Winn model
To determine whether local and sustained delivery of cytokine by RPCI -9597 ±IL -12 to the tumor /PBL xenograft could activate and promote the antitumor activity of the human PBL in the SCID -Winn model, irradiated RPCI -9597 ± IL -12 cells were co -engrafted with a mixed suspension of unmodified RPCI -2E9 human lung tumor cells and human PBL ( at an effector to target ratio of 2:1 ) into SCID mice. Allogeneic cells (with respect to the tumor ) were employed for the delivery of IL -12 because this approach potentially represents a clinically more feasible alternative to the use of autologous gene -modified tumor cells, and has been used successfully to induce tumor-specific immunity in murine models. 14 To determine whether an activation of the human PBL was induced by the local release of IL -12 from RPCI -9597 ± IL-12 cells in the SCID -Winn model, sera were collected from IL -12 ± treated and control mice at several time points after inoculation of cells and tested for the presence of human IFN -. The results indicate that human PBL produced significant quantities of IFN -when coengrafted with RPCI -2E9 and irradiated RPCI -9597 ±IL -12 cells, whereas irradiated nontransfected RPCI -9597 cells co -engrafted with tumor were unable to augment IFNproduction by the PBL (Fig 3) . The induction of IFN -by RPCI -9597 ±IL -12 was blocked in vivo by the addition of an anti ±hIL -12 monoclonal antibody confirming that the IL -12 produced by RPCI -9597± IL -12 cells was necessary for the activation of the human PBL ( Fig 3) . IFN -was not detected in the sera of mice when RPCI -9597 ± IL-12 cells were co-engrafted with tumor cells in the absence of PBL, and irradiated RPCI -9597 ±IL -12 cells did not produce IFN -in vitro ( data not shown ), demonstrating that the human PBL was the source of the human IFN -detected in the mouse sera. No human IL -12 could be detected in the sera of the mice that received RPCI -9597± IL -12 cells, suggesting that the IL -12 released from the cells was confined to the tumor /PBL microenvironment (data not shown).
To determine whether the activation of the human PBL by IL -12 resulted in the augmentation of their antitumor activity in vivo, tumor growth was monitored in mice engrafted with irradiated gene -modified cells, tumor, and PBL. In the absence of IL -12 ±secreting tumor cells, no tumor suppression is observed at an effector cell to tumor target ratio of 2:1 ( 2Â10 6 PBL and 1Â10 6 RPCI -2E9 cells). Co -engraftment of irradiated RPCI -9597± IL -12 cells with viable RPCI -2E9 tumors ( at a 2:1 PBL:tumor cell ratio ) resulted in the suppression of tumor engraftment in 70% of the mice ( Table 1) . Treatment of mice with an anti ± IL-12 antibody resulted in the loss of tumor suppression with tumors growing in four of five mice by week 8, indicating that the antitumor activity was IL -12± dependent. IL-12 therapy ( i.e., injection of IL -12 ±secreting tumor cells) in the absence of human PBL had no effect on tumor growth, demonstrating that IL -12 was not acting directly on tumor cells to suppress their growth, and that the antitumor effect was mediated by the human PBL (Table 1) . Tumor suppression was independent of the source of IL -12 or the histological type of human tumor because essentially identical results were obtained when RPCI -2E9 cells were used to deliver IL -12 to either RPCI -2E9 or to RPCI -9530 tumors (a human lung adenocarcinoma cell line; data not shown). We conclude that irradiated pCMVIL -12neo ± transfected human tumor cells deliver physiologically relevant levels of biologically active human IL -12 to the xenografts, resulting in the suppression of human tumor cell growth that is mediated by human PBL in the SCID -Winn model.
Antitumor effect of IL12 -transfected cells is dose -dependent
Previous studies have established that cytokine concentration is critical to effective augmentation ( or inhibition ) of lymphocyte activity in vitro and in vivo. 15, 16 To determine the optimal dose of RPCI -9597 ± IL -12 cells needed for proper activation of the human PBL, we titrated the quantity of IL-12 ±modified cells used in the SCID -Winn model. Irradiated, transfected (RPCI -9597 ±IL -12 ), and irradiated nontransfected ( RPCI -9597 ) cells were mixed at different ratios ( keeping the total irradiated cell number constant ) and co -injected with nonirradiated RPCI -2E9 tumor cells and PBL into SCID mice. As shown in Figure 4 , tumor suppression was directly proportional to the number of IL-12 ± transfected cells delivered, and the highest antitumor efficacy (60% of mice remaining tumor-free ) was obtained with a dose of 1Â10 6 RPCI -9597 ± IL-12 cells ( $3.5 ng IL -12 /day ). Use of higher numbers of RPCI9597 ±IL -12 ( 2± 5Â10 6 /mouse) did not result in a significant improvement of , and allogeneic PBL ( 2Â10 6 ), and were bled on days 1, 3, 5, and 7 after engraftment. Mice in the control group received irradiated, nontransfected RPCI -9597 cells instead of RPCI -9597 ± IL -12 cells. The difference between the IL -12 and the control groups was significant on days 1 and 3 ( P .011 ) and not significant on days 5 and 7 ( P ! .181 ) as determined by one -tailed Student's t test. Each bar represents an average of five mice, and error bars correspond to standard deviation. tumor suppression ( 70% of mice remaining tumor-free ).
At very high doses of RPCI -9597 ± IL -12 cells (1Â10 7 / mouse), loss of tumor suppression was observed (20% of mice remaining tumor-free; data not shown ), suggesting that higher levels of IL -12 result in a loss of the augmented PBL activity. These results suggest that $3.5 ng /day of IL -12 secreted locally is sufficient and perhaps optimal for inducing the antitumor activity of human PBL.
Tumor suppression induced by IL -12 in the SCID -Winn model requires the presence of CD8 + and CD56 + cells within the xenograft
To determine which lymphocyte subsets were responsible for the antitumor effect seen with IL-12 gene therapy in the SCID -Winn assay, PBL subset depletion studies were done. Live RPCI -2E9 tumor cells were co-injected with irradiated RPCI -9597 ±IL -12 cells and PBL (at an effector:target ratio of 2:1 ) that had been depleted in vitro (i.e., prior to engraftment ) of CD8 + , CD4 + , or CD56 + cells. Mockdepleted PBLs were used as a positive control, whereas a group of mice not receiving any PBL served as a negative control. As shown in Figure 5 , tumors developed in 100% of the mice inoculated with CD8 + -depleted PBL. Depletion of CD56 + cells from the PBL also impaired tumor suppression, with 60% of mice developing tumors. However, tumor development in the NK cell ±depleted group was significantly slower ( tumors became palpable by week 6 as opposed to week 2 in the CD8 -depleted group ). No loss of tumor suppression was observed when CD4 + -depleted or mock -depleted PBLs were used, indicating that in this model, CD8 + T and CD56 + NK cells were primarily responsible for the antitumor activity of IL -12.
DISCUSSION
We establish here that irradiated human tumor cells transfected with the human IL -12 expression vector pCMVIL12neo produce physiologically relevant levels of bioactive IL -12 that can promote the tumor-suppressive activity of human PBL in the microenvironment of the tumor /PBL xenograft. The antitumor activity of the human PBL is dependent on the dose of IL -12 ±transfected cells delivered and is mediated, in part, by the CD8 + T and NK cells in our model. These results confirm and extend our previous observations that the SCID -Winn model represents a viable model for the preclinical evaluation of cytokine-based human immunotherapy protocols. 9, 17 The SCID -Winn model offers significant advantages over conventional in vitro assays that utilize human lymphocytes and tumor cells for the evaluation of immunotherapy protocols. The ability to monitor in vivo the effect of immune modulators on the interactions between human PBL and tumors for extended periods ( i.e., up to 12± 14 weeks) represents one such advantage. Also, the selected protocols are evaluated in the context of a tumor microenvironment 6 / mouse in each group ( n = 5 ). Tumor growth was monitored for 12 weeks. Log -rank analysis was applied to determine the significance of the differences between the plots. Tumor development was significantly different between the group that received the highest dose of IL -12 ( 1Â10 6 RPCI -9597 ± IL -12 cells ) and the control group ( no IL -12, P = .0074 ), and the groups that received the two lowest doses of IL -12 ( 1Â10 4 and 5Â10 4 cells, P = .0132 and .0265, respectively ). The difference between the highest IL -12 dose group and the second highest group ( 2.5Â10 HESS, EGILMEZ, SHIROKO, ET AL: HUMAN TUMOR MODEL FOR EVALUATING CANCER IMMUNOTHERAPY with stroma and vasculature, which is not possible in in vitro studies. Furthermore, the SCID -Winn model provides an opportunity to study the effect of immunotherapy on the growth, invasion, and metastasis of human tumors using cell lines that metastasize following s.c. inoculation. While the SCID -Winn model provides an attractive preclinical assay for evaluating human cytokine -based therapies, several limitations of the model must also be addressed. One obvious pitfall is the fact that the human cells are engrafted in a xenogeneic environment. This leads to the development of both host -versus -graft (HVG ) responses and graft -versus -host disease ( GVHD ). 18 HVG responses in SCID mice involve antihuman cell activity of murine NK cells, macrophages, and granulocytes. HVG can be significantly reduced by depletion of murine NK cells with antibodies prior to the engraftment of human PBL and tumor. 19 At the same time, human PBL inoculated i.p. recognize and respond vigorously to murine tissue antigens. 20 GVHD not only affects the health of the host but also severely limits the ability of the human PBL to respond to human tumor antigens. 20, 21 We found that co-inoculation of tumor cells and PBL into a s.c. site minimizes GVHD by limiting the exposure of the human PBL to mouse antigens and preserves the ability of the PBL to react to human tumors. 9 The antitumor immunity observed here is alloreactive in nature since the tumor and the PBL are obtained from different individuals. Therefore, the CD8 + T-cell ± dependent antitumor response is likely due, in large part, to the recognition of allogeneic MHCI molecules present on the tumor cells and, as such, is not truly representative of a patient's response to their tumor. At the same time, the observed tumor suppression is not simply a threshold effect and requires both the presence of sufficient numbers of human PBL and optimal doses of IL-12 ( Figures 4 and 5 ) . Consequently, the SCID -Winn model in its allogeneic setting is useful for evaluating the ability of selected immunostimulatory agents to induce an allo -specific activation of human PBL and their ability to suppress tumor growth in vivo. We previously demonstrated that tumor cells and PBL from the same patient can also be engrafted in SCID mice and that the autologous PBLs also display antitumor activity. 17 In the autologous setting, the SCIDWinn model provides the additional capability to evaluate the ability of cytokines to augment a pre -existing cognitive antitumor response ( i.e., CD4 + and/ or CD8 + T cells ) as well as the innate antitumor activity of the PBL. Therefore, depending on the nature of the PBL and the tumor, it is possible to evaluate different antitumor mechanisms and the role of cytokines in these responses using our model.
The loss of tumor suppression at high local doses of human IL -12 ($35 ng/day ) in our studies suggests a bellshaped dose ± response curve for this cytokine. Similar effects have been observed with IL-2, which, at high doses, was found to induce the up-regulation of Fas and Fas ligand expression on activated T cells, resulting in their apoptotic death. 22 In the case of IL -12, a dose -dependent suppression of immunity, especially that of T-cell activity, has been demonstrated in murine models. 16 This suppression was found to be mediated by high levels of nitric oxide, which is released from the macrophages in response to up-regulation of IFN -. 23 It is possible that a similar toxicity occurs in our model at high doses of IL -12, resulting in the loss of PBL function.
Our results confirm the observations of others in murine models that antitumor immunity can be enhanced effectively when allogeneic cells are used to deliver the cytokine to tumors. 12, 13 The demonstration of the feasibility of this strategy using human tumors and effector cells has important clinical implications because a well -characterized, irradiated, cytokine gene ± modified allogeneic cell line provides a simpler, less expensive, and more universal alternative to the use of autologous cells for delivery of cytokines to tumors. Use of allogeneic cell lines for cytokine delivery also provides the opportunity for in situ vaccination of established tumors, which has been shown to be superior to vaccination with irradiated tumor cells and cytokine adjuvant. 24 Finally, cytokine-based immunotherapeutic strategies that do not involve gene modification can also be evaluated in the SCID -Winn model. We have previously demonstrated that bolus systemic delivery of soluble cytokines augments the antitumor activity of human PBL in this model. 9 More recently, we reported that slow, sustained release of human IL -2 and IL -12 from biodegradable polylactic acid microspheres at the site of the tumor can induce the activation of human PBL, resulting in the suppression of tumor growth in the SCID -Winn model. 17 Collectively, these data establish the utility of SCID -Winn model as a simple and versatile tool for rapid preclinical evaluation and optimization of different cytokine -based human cancer immunotherapy protocols in vivo.
